S&P 500   4,596.59 (+1.28%)
DOW   35,266.87 (+1.99%)
QQQ   385.23 (+0.55%)
AAPL   166.13 (+2.65%)
MSFT   323.60 (+0.18%)
FB   315.29 (+2.75%)
GOOGL   2,849.86 (+0.35%)
AMZN   3,451.51 (+1.82%)
TSLA   998.27 (-1.65%)
NVDA   293.21 (-4.47%)
BABA   120.84 (+7.93%)
NIO   32.20 (+0.16%)
CGC   9.97 (-0.20%)
AMD   136.15 (-5.46%)
GE   96.53 (+4.05%)
MU   82.33 (+0.87%)
T   23.48 (+0.09%)
F   19.27 (+0.68%)
DIS   150.15 (+2.69%)
PFE   52.27 (-3.69%)
AMC   28.60 (-1.41%)
ACB   5.88 (+1.03%)
BA   204.97 (+3.26%)
S&P 500   4,596.59 (+1.28%)
DOW   35,266.87 (+1.99%)
QQQ   385.23 (+0.55%)
AAPL   166.13 (+2.65%)
MSFT   323.60 (+0.18%)
FB   315.29 (+2.75%)
GOOGL   2,849.86 (+0.35%)
AMZN   3,451.51 (+1.82%)
TSLA   998.27 (-1.65%)
NVDA   293.21 (-4.47%)
BABA   120.84 (+7.93%)
NIO   32.20 (+0.16%)
CGC   9.97 (-0.20%)
AMD   136.15 (-5.46%)
GE   96.53 (+4.05%)
MU   82.33 (+0.87%)
T   23.48 (+0.09%)
F   19.27 (+0.68%)
DIS   150.15 (+2.69%)
PFE   52.27 (-3.69%)
AMC   28.60 (-1.41%)
ACB   5.88 (+1.03%)
BA   204.97 (+3.26%)
S&P 500   4,596.59 (+1.28%)
DOW   35,266.87 (+1.99%)
QQQ   385.23 (+0.55%)
AAPL   166.13 (+2.65%)
MSFT   323.60 (+0.18%)
FB   315.29 (+2.75%)
GOOGL   2,849.86 (+0.35%)
AMZN   3,451.51 (+1.82%)
TSLA   998.27 (-1.65%)
NVDA   293.21 (-4.47%)
BABA   120.84 (+7.93%)
NIO   32.20 (+0.16%)
CGC   9.97 (-0.20%)
AMD   136.15 (-5.46%)
GE   96.53 (+4.05%)
MU   82.33 (+0.87%)
T   23.48 (+0.09%)
F   19.27 (+0.68%)
DIS   150.15 (+2.69%)
PFE   52.27 (-3.69%)
AMC   28.60 (-1.41%)
ACB   5.88 (+1.03%)
BA   204.97 (+3.26%)
S&P 500   4,596.59 (+1.28%)
DOW   35,266.87 (+1.99%)
QQQ   385.23 (+0.55%)
AAPL   166.13 (+2.65%)
MSFT   323.60 (+0.18%)
FB   315.29 (+2.75%)
GOOGL   2,849.86 (+0.35%)
AMZN   3,451.51 (+1.82%)
TSLA   998.27 (-1.65%)
NVDA   293.21 (-4.47%)
BABA   120.84 (+7.93%)
NIO   32.20 (+0.16%)
CGC   9.97 (-0.20%)
AMD   136.15 (-5.46%)
GE   96.53 (+4.05%)
MU   82.33 (+0.87%)
T   23.48 (+0.09%)
F   19.27 (+0.68%)
DIS   150.15 (+2.69%)
PFE   52.27 (-3.69%)
AMC   28.60 (-1.41%)
ACB   5.88 (+1.03%)
BA   204.97 (+3.26%)
NYSE:TAK

Takeda Pharmaceutical Stock Forecast, Price & News

$13.66
+0.17 (+1.26%)
(As of 12/6/2021 12:39 PM ET)
Add
Compare
Today's Range
$13.47
$13.68
50-Day Range
$13.17
$17.01
52-Week Range
$13.17
$19.97
Volume
86,088 shs
Average Volume
2.34 million shs
Market Capitalization
$43.23 billion
P/E Ratio
8.65
Dividend Yield
2.54%
Beta
0.95
30 days | 90 days | 365 days | Advanced Chart
Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.


Takeda Pharmaceutical logo

About Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Headlines

Takeda Pharmaceutical (NYSE:TAK) Reaches New 1-Year Low at $13.39
November 29, 2021 |  americanbankingnews.com
Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval
November 25, 2021 |  finance.yahoo.com
Takeda Pharmaceutical (NYSE:TAK) Reaches New 52-Week Low at $13.81
November 22, 2021 |  americanbankingnews.com
Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
November 22, 2021 |  uk.finance.yahoo.com
Takeda Pharmaceutical (NYSE:TAK) Sees Strong Trading Volume
November 16, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
47,000
Year Founded
1781

Sales & Book Value

Annual Sales
$30.17 billion
Cash Flow
$3.70 per share
Book Value
$15.31 per share

Profitability

Net Income
$3.53 billion
Pretax Margin
15.38%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
3,164,500,000
Free Float
N/A
Market Cap
$43.23 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/28/2021
Today
12/06/2021
Next Earnings (Estimated)
2/03/2022
Fiscal Year End
3/31/2022

Social Links


MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

992nd out of 1,390 stocks

Pharmaceutical Preparations Industry

472nd out of 673 stocks

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -












Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

Is Takeda Pharmaceutical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Takeda Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.
View analyst ratings for Takeda Pharmaceutical
or view top-rated stocks.

How has Takeda Pharmaceutical's stock price been impacted by Coronavirus (COVID-19)?

Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TAK stock has decreased by 20.3% and is now trading at $13.66.
View which stocks have been most impacted by COVID-19
.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Takeda Pharmaceutical
.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) released its earnings results on Thursday, October, 28th. The company reported $0.45 earnings per share for the quarter. The company had revenue of $7.67 billion for the quarter. Takeda Pharmaceutical had a net margin of 15.78% and a trailing twelve-month return on equity of 12.66%.
View Takeda Pharmaceutical's earnings history
.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.34 per share and currently has a dividend yield of 2.54%. The dividend payout ratio of Takeda Pharmaceutical is 21.52%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 36.56% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of $3.530-$3.530 for the period. The company issued revenue guidance of $30.22 billion-$30.22 billion.

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:
  • Christophe Weber, President, CEO & Representative Director
  • Constantine Saroukos, Chief Financial Officer & Director
  • Andrew S. Plump, Director, Research & Development President
  • Michael E. Mendelsohn, Chief Medical & Scientific Officer
  • Norimasa Takeda, Chief Accounting Officer & Corporate Controller

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Glenview Capital Management LLC (0.26%), Macquarie Group Ltd. (0.15%), Goldman Sachs Group Inc. (0.08%), Renaissance Technologies LLC (0.07%), Morgan Stanley (0.06%) and BlackRock Inc. (0.06%).

Which major investors are selling Takeda Pharmaceutical stock?

TAK stock was sold by a variety of institutional investors in the last quarter, including Glenview Capital Management LLC, GMT Capital Corp, CIBC Asset Management Inc, Millennium Management LLC, Franklin Resources Inc., Renaissance Technologies LLC, Comerica Bank, and Janus Henderson Group PLC.

Which major investors are buying Takeda Pharmaceutical stock?

TAK stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Barclays PLC, Van ECK Associates Corp, EP Wealth Advisors LLC, Russell Investments Group Ltd., BlackRock Inc., Summit Global Investments, and FNY Investment Advisers LLC.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $13.66.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical has a market capitalization of $43.23 billion and generates $30.17 billion in revenue each year. The company earns $3.53 billion in net income (profit) each year or $1.58 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

Takeda Pharmaceutical employs 47,000 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?

The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.

When was Takeda Pharmaceutical founded?

Takeda Pharmaceutical was founded in 1781.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takeda.com.

Where are Takeda Pharmaceutical's headquarters?

Takeda Pharmaceutical is headquartered at 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.